Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study

Cancer

Volumn 80, Issue 12 SUPPL., 1997, Pages 2712-2720

  Molthoff, Carla F M ^a   Prinssen, Helma M ^a   Kenemans, Peter ^a   Van Hof, Arjan C ^a   Den Hollander, Wim ^a   Verheijen, René H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody dose escalation; Chimeric; Immune response; Intravenous; Monoclonal antibody; MOv18; Ovarian carcinoma; Toxicity

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY C MOV 18 I 131; MONOCLONAL ANTIBODY I 131; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; FEMALE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; VOMITING;

EID: 0031472381     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971215)80:12+<2712::aid-cncr50>3.0.co;2-b     Document Type: Conference Paper

References (29)

1. Venesmaa P. Epithelial ovarian cancer: impact of surgery and chemotherapy on survival during 1977-1990. Obstet Gynecol 1994;84:8-11.
2. Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, van Oosterom AT, Willemse PHB, Vermorken JB, et al. Long-term survival in ovarian cancer. Mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 1991;27:1367-72.
3. DiSaia PJ, Creasman WT. Epithelial ovarian cancer. In: DiSaia PJ, Creasman WT, editors. Clinical Gynecologic Oncology. St. Louis, MO: Mosby Year Book, 1993;333-425.
4. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991;51:5329-38.
5. Coney LR, Tomasetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, et al. Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991;51:6125-32.
6. Miotti S, Canevari S, Menard S, Mezzanzanica D, Porro G, Pupa SM, et al. Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specifity. Int J Cancer 1987;39:297-303.
7. Boerman OC, van Niekerk CC, Makkink WK, Hanselaar AGJM, Kenemans P, Poels LG. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens. Int J Gynecol Pathol 1991;10:15-25.
8. Molthoff CFM, Buist MR, Kenemans P, Pinedo HM, Boven E. Experimental and clinical analysis of a chimeric monoclonal antibody MOv18 reactive with an ovarian cancer associated antigen. J Nucl Med 1992;33:2000-5.
9. Buist MR, Kenemans P, den Hollander W, Vermorken JB, Molthoff CFM, Burger CW, et al. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab′)2 fragments in ovarian carcinoma patients. Cancer Res 1993;53:5413-8.
10. Crippa F, Bolis G, Seregni E, Gavoni N, Scarfone G, Ferraris C, et al. Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. Eur J Cancer 1995;31A:686-90.
11. Bruggeman M, Williams GT, Bindon CI, Clark MR, Walker MR, Jefferis R, et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61.
12. Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Dadonna P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specifity. Proc Natl Acad Sci USA 1988;85:4852-6.
13. Coney LR, Mezzanzanica D, Sanborn D, Casalini P, Colnaghi MI, Zurawski VR. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing. Cancer Res 1994;2448-55.
14. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-83.
15. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA. Determination of the immunoreactive fraction of radiolabeled monoclonal antibody by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77-89.
16. Buist MR, Molthoff CFM, Kenemans P, Meijer CJLM. Distribution of OV-TL 3 and MOv18 in normal and malignant ovarian tissue. J Clin Pathol 1995;48:631-6.
17. Buist MR, Kenemans P, Van Kamp GJ, Haisma HJ. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays. Cancer Immunol Immunother 1995;40:24-30.
18. Tibben JG, Buijs WCAM, Boerman OC, Massuger LFAG, Koenders EB, Schijf CPT, et al. Intraperitoneal administration of chimeric monoclonal antibody MOv18 IgG in ovarian carcinoma patients: pharmacokinetics, biodistribution and dosimetry. In: Tibben C, editor. Diagnostic and Therapeutic Targeting of Ovarian Cancer Using Monoclonal Antibodies. Nijmegen: Druk Benda, 1995;111-30.
19. Molthoff CFM, Kenemans P, van Hof A, Buist M, den Hollander W, Verheijen R, et al. Influence of the route of administration on targeting ovarian cancer tissue with chimeric monoclonal antibody MOv18 (c-MOv18). Proceedings of the 11th International Hammersmith Conference: Advances in the Applications of Monoclonal Antibodies in Clinical Oncology, London: Antisoma Ltd., 1994;22.
20. Goodman GE, Hellström I, Yelton DE, Murray JL, O'Hara S, Meaker E, et al. Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with nonsmall-cell lung, colon, and breast cancer. Cancer Immunol Immunother 1993;36:267-73.
21. Knox SJ, Levy R, Hodgkinson S, Bell R, Brown S, Wood GS, et al. Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 1991;77:20-30.
22. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA 1989;86;4220-4.
23. Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, et al. Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992;33:23-9.
24. Sharkey RM, Primus FJ, Goldenberg DM. Antibody protein dose and radioimmunodetection of GW-39 human colon tumor xenografts. Int J Cancer 1987;39:611-7.
25. Boerman OC, Sharkey RM, Wong GY, Blumenthal RD, Aninipot RL, Goldenberg DM. Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor. Cancer Immunol Immunother 1992;35:127-34.
26. Worlock AJ, Zalutsky MR, Metzgar RS. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1. Cancer Res 1990;50:7246-51.
27. Rosenblum MG, Levin B, Roh M, Hohn D, McCabe R, Thompson L, et al. Clinical pharmacology and tissue disposition studies of I-131-labeled anticolorectal carcinoma human monoclonal antibody LiCO 16.88. Cancer Immunol Immunother 1994;39:397-400.
28. van Hof AC, Molthoff CFM, Davies Q, Perkins AC, Verheijen RHM, Kenemans P, et al. Biodistribution of indium-111 labeled engineered human antibody CTM01 in ovarian cancer patients: influence of protein dose. Cancer Res 1996; 56:5179-85.
29. Blumenthal RD, Fand I, Sharkey RM, Boerman OC, Kashi R, Goldenberg DM. The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study. Cancer Immunol Immunother 1991; 33:351-8.